A Novel Toolkit of SARS-CoV-2 Sub-Genomic Replicons for Efficient Antiviral Screening
Viruses · 2025
DOI: 10.3390/v17050597 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Maximilian Erdmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, Replicon. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Wellcome Trust, Chinese Academy of Medical Sciences, Innovation Fund for Medical Science.
Abstract (Originalsprache)
SARS-CoV-2 is classified as a containment level 3 (CL3) pathogen, limiting research access and antiviral testing. To address this, we developed a non-infectious viral surrogate system using reverse genetics to generate sub-genomic replicons. These replicons contained the nsp1 mutations K164A and H165A and had the spike, membrane, ORF6, and ORF7a coding sequences replaced with various reporter and selectable marker genes. Replicons based on the ancestral Wuhan Hu-1 strain and the Delta variant of concern were replication-competent in multiple cell lines, as assessed by Renilla luciferase activity, fluorescence, immunofluorescence staining, and single-molecule fluorescent in situ hybridization. Antiviral assays using transient replicon expression showed that remdesivir effectively inhibited both replicon and viral replication. Ritonavir and cobicistat inhibited Delta variant replicons similarly to wild-type virus but did not inhibit Wuhan Hu-1 replicon replication. To further investigate the impact of nsp1 mutations, we generated a recombinant SARS-CoV-2 virus carrying the K164A and H165A mutations. The virus exhibited attenuated replication across a range of mammalian cell lines, was restricted by the type I interferon response, and showed reduced cytopathic effects. These findings highlight the utility of sub-genomic replicons as reliable CL2-compatible surrogates for studying SARS-CoV-2 replication and drug activity mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.
- Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford OX3 7BN, UK.
- Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
- Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
ORCID-Profile: Maximilian Erdmann, Maia Kavanagh Williamson, Tuksin Jearanaiwitayakul, Jane A McKeating, David A Matthews
Förderung
- Medical Research Council
- Wellcome Trust
- Chinese Academy of Medical Sciences, Innovation Fund for Medical Science
- United States Food and Drug Administration
- UK Research and Innovation/Medical Research Council
- Elizabeth Blackwell Institute
- Wellcome Investigator Award (IA)
- Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China
Zitieren
APA
Erdmann, M., Wing, P. A. C., Webb, I., Kavanagh Williamson, M., Jearanaiwitayakul, T., Sullivan, E., Bazire, J., Shytaj, I. L., McKeating, J. A., Matthews, D. A., & Davidson, A. D. (2025). A Novel Toolkit of SARS-CoV-2 Sub-Genomic Replicons for Efficient Antiviral Screening. Viruses. https://doi.org/10.3390/v17050597
Vancouver
Erdmann M, Wing PAC, Webb I, Kavanagh Williamson M, Jearanaiwitayakul T, Sullivan E, et al. A Novel Toolkit of SARS-CoV-2 Sub-Genomic Replicons for Efficient Antiviral Screening. Viruses. 2025. doi:10.3390/v17050597
BibTeX
@article{Erdmann2025,
author = {Erdmann, Maximilian and Wing, Peter A C and Webb, Isobel and Kavanagh Williamson, Maia and Jearanaiwitayakul, Tuksin and Sullivan, Edward and Bazire, James and Shytaj, Iart Luca and McKeating, Jane A and Matthews, David A and Davidson, Andrew D},
title = {A Novel Toolkit of SARS-CoV-2 Sub-Genomic Replicons for Efficient Antiviral Screening},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17050597}
}
EUVIMED